Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus temozolomide in recently diagnosed glioblastoma
ISRCTN84434175Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Ipilimumab + temozolomide with Temozolomide (2 arms). Primary endpoint: Overall survival. Started Dec 2018; status: completed.
02
Drugs
ipilimumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN84434175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84434175.